Partnership for Applied Research in Fracture Prevention Programs for the Elderly (OPTI-FRAC)
26 oktober 2018 bijgewerkt door: Isabelle Gaboury, Université de Sherbrooke
During their lifetime, approximately 50% of Canadian women and 30% of Canadian men will experience at least one fracture due to bone fragility (FF).
Evidence is growing regarding prevention programs' effectiveness to prevent falls, but prevention of fractures through fall prevention programs has enjoyed limited success.
Falls prevention programs and post-fracture screening programs leading to pharmacological treatment are very different strategies, with a shared ultimate goal.
Coordination between those who repair fractures and those who manage the patient to prevent the next fracture is critical.
The overarching aim of this proposal is to generate evidence-based knowledge about the effectiveness and cost-effectiveness of an integrated FF prevention program, as well as a portrait of the barriers and facilitating factors for such programs.
More specifically, the objectives are: 1) to combine existing fall prevention and post-fracture management programs in the province of Quebec into integrated FF prevention programs; 2) to compare the performance of these integrated programs to control sites, using a pragmatic study design; 3) to identify barriers as well as factors that improve effectiveness across different implementation milieu; and 4) to develop and engage in active knowledge transfer activities in Quebec regions where integrated FF prevention programs are neither adequately nor successfully implemented.
Drawing upon the literature on integrated healthcare, fall and fracture prevention, we hypothesize that an integrated FF program can reduce the risk of a subsequent fracture by at least 30% in the population of interest.
The proposed team is poised to develop new interdisciplinary collaborations among healthcare practitioners and decision makers involved in the prevention of FFs.
The program is built upon existing healthcare and structures and programs and in turn, will truly measure the effectiveness of an integrated FF prevention program.
The results will ultimately lead to improvements in the existing knowledge base, address policy-relevant and health systems problems, and assist in the design and implementation of FFs prevention programs.
Studie Overzicht
Toestand
Onbekend
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Werkelijk)
631
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Quebec
-
Amos, Quebec, Canada, J9T 2S2
- Centre hospitalier Hôtel-Dieu d'Amos
-
Chandler, Quebec, Canada, G0C 1K0
- CSSS du Roché Percé (Centre hospitalier de Chandler)
-
Gatineau, Quebec, Canada, J8Y 1W7
- Hôpital de Hull
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Hôpital Charles LeMoyne
-
Montreal, Quebec, Canada, H1T 2M4
- Hopital Maisonneuve-Rosemont
-
Montreal, Quebec, Canada, H4J 1C5
- Hôpital Sacré-Coeur de Montréal
-
Montreal, Quebec, Canada, H2E1S6
- Hôpital Jean-Talon
-
Saint-Charles-Borromée, Quebec, Canada, J6E 6J2
- Centre hospitalier régional de Lanaudière
-
Sherbrooke, Quebec, Canada, J1H5N4
- Centre Hospitalier Universitaire de Sherbrooke
-
St-Jérôme, Quebec, Canada, J7Z 5T3
- CSSS de St-Jérôme (Hôpital régional de St-Jérôme)
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
50 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- 50 years of age and over
- must have a primary care physician
- must be able to follow simple instructions
- must have sustained a fragility fracture within three months of the recruitment date.
Exclusion Criteria:
- severe kidney insufficiency (grade 4 or 5)
- advanced stage of cancer
- fracture to sites not commonly associated with osteoporosis such as toe, finger, hand, foot, ankle, patella, head, and cervical spine.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Onderzoek naar gezondheidsdiensten
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: Controlegroep
|
|
|
Experimenteel: Integrated program
Participants will be involved in an integrated interorganisational fragility fracture prevention program, which combines both post-fracture management as well as fall prevention strategies.
The intervention will last up to 18 months.
|
Each participant's primary care physician will receive written information containing a presumed osteoporosis diagnosis, investigations to be performed, correct interpretation of any bone densitometry results in the context of a fragility fracture, and treatment options.
The study coordinator will be responsible for orienting the participant to an appropriate local fall prevention program.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Incidence of secondary fragility fracture
Tijdsspanne: 18 months post recruitment
|
18 months post recruitment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Initiation of osteoporosis treatment by the primary care physician
Tijdsspanne: At 6, 12, 18, and 60 months post recruitment
|
Osteoporosis treatment includes bisphosphonates or other effective osteoporosis drugs.
|
At 6, 12, 18, and 60 months post recruitment
|
|
Compliance with osteoporosis treatment.
Tijdsspanne: At 6, 12, 18, and 60 months post recruitment
|
The data collected from the participant will be validated with the participant's pharmacist through the medication possession ratio.
The medication possession ratio is measured from the first to the last prescription, with the denominator being the duration from index to the exhaustion of the last prescription and the numerator being the days supplied over that period from first to last prescription and the numerator being the total number of days in the interval.
|
At 6, 12, 18, and 60 months post recruitment
|
|
Time to first fall event
Tijdsspanne: Within the first 18 months post recruitment
|
Within the first 18 months post recruitment
|
|
|
Incidence of secondary fragility fractures.
Tijdsspanne: At 24, 36, 48 and 60 months post recruitment
|
At 24, 36, 48 and 60 months post recruitment
|
|
|
Number of clinically significant fall events.
Tijdsspanne: At 18, 24, 36, 48 and 60 months post recruitment
|
At 18, 24, 36, 48 and 60 months post recruitment
|
|
|
Fall-related hospitalizations
Tijdsspanne: At 18, 24, 36, 48 and 60 months post recruitment
|
Fall-related hospitalizations will be recorded in the participant diary and at each telephone follow-up, and validated with the participant's hospital records.
|
At 18, 24, 36, 48 and 60 months post recruitment
|
|
Fragility fracture-related death
Tijdsspanne: At 18, 24, 36, 48 and 60 months post recruitment
|
Fragility fracture-related death will be confirmed from a provincial administrative database (Regie de l'assurance maladie du Quebec - RAMQ).
|
At 18, 24, 36, 48 and 60 months post recruitment
|
|
Participants' quality of life
Tijdsspanne: At 18, 24, 36, 48 and 60 months post recruitment
|
Euro-QOL
|
At 18, 24, 36, 48 and 60 months post recruitment
|
|
Practice of physical activities
Tijdsspanne: At 6, 12, 18, 24, 36, 48 and 60 months post recruitment
|
CHAMPS
|
At 6, 12, 18, 24, 36, 48 and 60 months post recruitment
|
|
Fragility fracture-related costs
Tijdsspanne: At 18 and 60 months post recruitment
|
Medical costs from the participant's hospital record include: medical assessment, prescription and non-prescription drugs; and resource use related to the management of the fragility fracture and/or long-term complications, including hospitalization.
As well, lost days of work, annual income (if the participant is in the labour force), travel to the hospital and/or rehabilitation facilities, parking, and out-of-pocket expenses for drugs and rehabilitation devices (e.g.
splint) will be compiled.
Protocol-driven costs will be excluded, with the exception of the costs related to the participants' fall prevention program.
|
At 18 and 60 months post recruitment
|
|
Admission to a long-term care facility
Tijdsspanne: At 18, 24, 36, 48 and 60 months post recruitment
|
At 18, 24, 36, 48 and 60 months post recruitment
|
|
|
Participants' perceptions of care integration
Tijdsspanne: At 12 months post intervention
|
All participants' perceptions of care integration will be captured 12 months after the beginning of the intervention period, or following an early withdrawal from the study.
|
At 12 months post intervention
|
|
Intervention participant's satisfaction with the fragility fracture prevention program
Tijdsspanne: At 12 months post intervention
|
At 12 months post intervention
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Isabelle Gaboury, PhD, Université de Sherbrooke
- Hoofdonderzoeker: Hélène Corriveau, PhD pht, Université de Sherbrooke
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start
1 januari 2013
Primaire voltooiing (Werkelijk)
1 november 2016
Studie voltooiing (Verwacht)
1 juni 2019
Studieregistratiedata
Eerst ingediend
5 december 2012
Eerst ingediend dat voldeed aan de QC-criteria
5 december 2012
Eerst geplaatst (Schatting)
7 december 2012
Updates van studierecords
Laatste update geplaatst (Werkelijk)
29 oktober 2018
Laatste update ingediend die voldeed aan QC-criteria
26 oktober 2018
Laatst geverifieerd
1 oktober 2018
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CIHR grant # 267395
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .